FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 |
|--------------------------|-----------|
| Estimated average burden | |
| hours nor rechence: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | |
|--|---|---|
| Name and Address of Reporting Person* Kelderman Kim | 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |
| (Last) (First) (Middle) 614 MCKINLEY PLACE NE | 3. Date of Earliest Transaction (Month/Day/Year) 11/03/2025 | X Director 10% Owner X Officer (give title Other (specify below) Chief Executive Officer |
| (Street) MINNEAPOLIS MN 55413 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |
| (City) (State) (Zip) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | Execution Date, Transaction | | 4. Securities Ad Disposed Of (D | | | Securities Beneficially Owned Following Reported | Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---------------------------------|--|-----------------------------|------|------------------------------------|--------|---------------|--|---|---|-----------|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (mstr. 4) |
| Common Stock | 11/03/2025 | | F | | 2,303 | D | \$62.57 | 48,665 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| (e.g., puts, cans, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|---|---|--|---|---------------------------------|---|--|-----|---|--------------------|---|--|--|--|---|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transac Code (Ir 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 7. Title and Ar Securities Un- Derivative Sec 3 and 4) | derlying | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| Stock Option (Right to Buy) | \$47.6 | | | | | | | (1) | 08/07/2026 | Common Stock | 109,536 | | 109,536 | D | |
| Stock Option (Right to Buy) | \$66.97 | | | | | | | (1) | 08/05/2027 | Common Stock | 115,724 | | 115,724 | D | |
| Stock Option (Right to Buy) | \$120.46 | | | | | | | (1) | 08/06/2028 | Common Stock | 25,944 | | 25,944 | D | |
| Stock Options (Right to Buy) | \$94.52 | | | | | | | (1) | 08/15/2029 | Common Stock | 28,940 | | 28,940 | D | |
| Performance Restricted Stock Units | (2) | | | | | | | (3) | (3) | Common Stock | 8,873 | | 8,873 | D | |
| Performance Stock Options (Right to Buy) | \$84.61 | | | | | | | (3) | 08/15/2030 | Common Stock | 23,881 | | 23,881 | D | |
| Stock Options (Right to Buy) | \$84.61 | | | | | | | (4) | 08/15/2030 | Common Stock | 29,391 | | 29,391 | D | |
| Stock Options (Right to Buy) | \$52.83 | | | | | | | (5) | 11/01/2030 | Common Stock | 38,252 | | 38,252 | D | |
| Performance Restricted Stock Units | (2) | | | | | | | (3) | (3) | Common Stock | 9,423 | | 9,423 | D | |
| Performance Stock Options (Right to Buy) | \$68.54 | | | | | | | (3) | 02/01/2031 | Common Stock | 25,945 | | 25,945 | D | |
| Stock Options (Right to Buy) | \$68.54 | | | | | | | (6) | 02/01/2031 | Common Stock | 51,890 | | 51,890 | D | |
| Performance Restricted Stock Units | (2) | | | | | | | (7) | (7) | Common Stock | 51,261 | | 51,261 | D | |
| Restricted Stock Units | (2) | | | | | | | (8) | (8) | Common Stock | 17,087 | | 17,087 | D | |
| Stock Options (Right to Buy) | \$74.91 | | | | | | | (9) | 08/15/2034 | Common Stock | 69,061 | | 69,061 | D | |

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transac Code (In 8) | | Deriva Securi Acquir or Dispof (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | Date Securities Underlying | | | 8. Price of Derivative Security (Instr. 5) | Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|---|--|---|---------------------------------|---|---|--|---------------------|----------------------------|-----------------|----------------------------------|---|------------------------------|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| | | | | | | | | | | | | | | | |
| Performance Restricted Stock Units | (2) | | | | | | | (10) | (10) | Common Stock | 70,708 | | 70,708 | D | |
| Restricted Stock Units | (2) | | | | | | | (11) | (11) | Common Stock | 35,354 | | 35,354 | D | |
| Stock Options (Right to Buy) | \$53.6 | | | | | | | (12) | 08/15/2035 | Common Stock | 90,441 | | 90,441 | D | |

Explanation of Responses:

- 1. Fully exercisable.
- 2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 3. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- $4.\ Options\ to\ purchase\ 7,348\ shares\ vest\ on\ each\ of\ 8/15/2024,\ 8/15/2025\ and\ 8/15/2027\ and\ options\ to\ purchase\ 7,347\ shares\ vest\ on\ 8/15/2026.$
- 5. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- $6.\ Options\ to\ purchase\ 12,973\ shares\ vest\ on\ each\ of\ 2/1/2025\ and\ 2/1/2027,\ and\ options\ to\ purchase\ 12,972\ shares\ vest\ on\ each\ of\ 2/1/2028.$
- 7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- 8. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
- 9. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- 10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- $11.\ 11,785\ restricted\ stock\ units\ vest\ on\ each\ of\ 8/15/2026\ and\ 8/15/2027,\ and\ 11,784\ restricted\ stock\ units\ vest\ on\ 8/15/2028.$
- 12. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to 11/05/2025 Power of Attorney previously filed.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.